December 20, 2018
Authored and Edited by Katherine T. Leonard; Shana K. Cyr, Ph.D.
On December 11, 2018, FDA issued final guidance on interpreting the “Deemed to be a License” provision of BPCIA. The guidance provides FDA’s interpretation of the provision and its recommendations to sponsors of proposed protein products.
According to the guidance, an approved NDA for a biological product shall be deemed to be a BLA for the product as of the transition date, March 23, 2020. Examples of such products are provided in the guidance’s appendix. As of the transition date, the approved NDA will no longer exist, FDA will remove the product from the Orange Book, and FDA will no longer consider any listed patents as relevant for the timing of approving a 505(b)(2) application or ANDA for the product.
Regarding regulatory exclusivities, the guidance indicates that any unexpired period of exclusivity related to the approved NDA other than orphan drug exclusivity and pediatric exclusivity will cease to have any effect as of the transition date. In addition, the guidance indicates that the approved products will not be eligible for the 12-year exclusivity period for reference products first licensed as BLAs.
After the transition date, FDA will not approve any pending or tentatively approved NDAs for biological products subject to the provision. Instead, sponsors may withdraw these applications and resubmit them as BLAs or aBLAs, as appropriate.
FDA recommends that sponsors of proposed protein products intending to submit an NDA consider submitting a BLA instead. FDA recommends a sponsor intending to submit a 505(b)(2) application consider modifying their development program as appropriate to support submission of a BLA or aBLA.
More information about the provision can be found in FDA’s draft guidance on questions and answers about the provision and Finnegan’s related IP FDA Blog post.
Readers are encouraged to read the final guidance, also available on FDA's website.
abbreviated biologic license application (aBLA), Biologic License Application (BLA), Biologics Price Competition and Innovation Act (BPCIA), FDA Guidance, Food and Drug Administration (FDA), new drug application (NDA), Orange Book, Purple Book
Copyright © 2018 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
June 10-12, 2024
San Francisco
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
10th Annual Georgia Asian Pacific American Bar Association Gala
May 29, 2024
Atlanta
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.